Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

ConclusionsOver 2 years, compared with glipizide, dapagliflozin demonstrated greater glycaemic durability, sustained reductions in weight and systolic blood pressure and a low hypoglycaemia rate; however, genital infections and UTIs occurred more frequently.

Source: Diabetes, Obesity and Metabolism - July 10, 2014 Category: Endocrinology Authors: M. A. Nauck, S. Del Prato, S. Durán‐García, K. Rohwedder, A. M. Langkilde, J. Sugg, S. J. Parikh Tags: ORIGINAL ARTICLE Source Type: research